London-based virtual fertility service Apricity has landed €17m (£14.7m) in Series B funding for domestic and international expansion.
Apricity says it will launch in Spain this year, with Germany and Italy next on the list. The healthtech will also use the capital for UK growth and to develop of its technology, which provides personalised support through an app during fertility treatment.
Its service is offered by UK employee benefits providers such as AXA and Reward Gateway.
Caroline Noublanche, founder and CEO of Apricity, said: “We look forward to supporting more women and couples across Europe who are struggling to conceive and can now hope for a better, less stressful alternative option.”
Swiss healthtech investor MTIP led the Series B and was supported by Barcelona-based fund Iris Ventures. It follows on from the €6m (£5.1m) Series A round in June 2019.
Founded in 2018, earlier this year Apricity acquired Woom, a Madrid-based period tracking app for an undisclosed sum.
“Rather than focusing on just one part of the fertility journey, Apricity is using cutting-edge technology to transform the end-to-end experience for patients and has seen incredibly strong traction as a result,” said Christoph Kausch, managing partner, MTIP.
Marc Dietrich from MTIP will join Apricity’s board as part of the deal.
Montse Suarez, founder and managing partner at Iris Ventures, said: “There is no doubt Apricity is a stand-out in their field, using patient-centric technology to make a real impact in the lives of fertility patients, delivering high-quality care when and where patients need it most.”
According to the company, its fertility has a 46% success rate compared to the UK average of 31%.
Competitors include Béa Fertility, which provides home fertility treatment and ovulation tracking services.